M. Herold

Articles

Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia

H. Schulz;S. K. Klein;U. Rehwald;Maximilian F. Reiser, MD;S. Ibach;W. E. Aulitzky;M. Hensel;M. Herold;D. Huhn;U. Knauf;Michael Hallek, MDDirector;Volker Diehl, MD, PhD;Andreas Engert, MD, PhD

March 1st 2002

This phase II trial investigated the safety and efficacy of a combined-modality treatment with rituximab (Rituxan) and fludarabine (Fludara) in patients with fludarabine- and anthracycline-naive chronic lymphocytic lymphoma (CLL).

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Published: January 24th 2025 | Updated: February 6th 2025

FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

Published: September 13th 2024 | Updated: November 25th 2024

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Published: August 9th 2024 | Updated: August 14th 2024

Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets

Published: June 2nd 2024 | Updated: June 3rd 2024

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Published: May 6th 2024 | Updated: May 21st 2024

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

Published: August 26th 2011 | Updated: April 28th 2025

Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777